Drug intelligence / Profile preview

[68Ga]Ga-NOTA-R8B4

Development stage: Phase 2
Lead developer: Renji Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[68Ga]Ga-NOTA-R8B4 is a radiopharmaceutical designed for Positron Emission Tomography (PET) imaging. It comprises the radionuclide Gallium-68 ([68Ga]), which is chelated by 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and a targeting moiety designated R8B4. This tracer is specifically developed to target the Cluster of Differentiation 70 (CD70) oncofetal antigen, enabling non-invasive visualization of CD70 expression in various malignant cancers. It is currently under investigation for its diagnostic efficacy in conditions such as renal cancer (especially clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma.

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on [68Ga]Ga-NOTA-R8B4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-NOTA-R8B4.

Explore the full profile